Aquilo Partners
Overview
Aquilo Partners is an independent investment bank dedicated to the future of healthcare. With over twenty years of experience, they provide custom-tailored strategic and financial advisory services across the life science industry, focusing solely on enabling clients to advance life science innovation. Their services include mergers & acquisitions, partnerships, private placements, strategic advisory, and financial advisory. The team emphasizes a transparent, thoughtful approach to success, leveraging deep experience in the healthcare sector to address the specific needs of each client. Aquilo Partners has established a reputation as a leading life science advisor, advising on more than $20 billion in M&A and partnering transactions and raising over $8 billion in capital. They maintain top-tier relationships throughout the global life science industry, including biotechnology, big pharma, specialty pharma, medical devices, research tools, and diagnostics sectors.
Investment Focus
- Life science companies seeking strategic and financial advisory services in mergers & acquisitions, licensing/partnership transactions, and private placements.
Portfolio Companies
Reach Aquilo Partners directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Aquilo Partners
What sectors does Aquilo Partners invest in?
Aquilo Partners invests in Pharmaceuticals, Medical Devices, Diagnostics, Biotechnology and Research Tools, and is based in California, United States. Aquilo Partners is listed as a private investment firm in the ConnectSafely investor database.
What stage does Aquilo Partners invest at?
Aquilo Partners backs companies at Early Stage, Growth, Late Stage, Pre-IPO and Buyout, writing cheques of 1M - 50M.
Which regions does Aquilo Partners invest in?
Aquilo Partners invests across United States.
What companies has Aquilo Partners invested in?
Aquilo Partners's portfolio includes Matchpoint Therapeutics, Adverum Biotechnologies, Curio Biosciences, Kymera, Aldeyra and Swift Bioscience.
Last updated · Source: ConnectSafely investor database
